Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.fivestarequities.com/ and get exclusive access to our numerous stock reports.
Forest Laboratories, Inc. (NYSE: FRX) shares spiked 5.03 percent to close at $46.54 a share Tuesday. The stock traded between $43.78 and $47.10 on volume 5.33 million shares traded. The company reported net sales were $811.4 million for the second quarter of fiscal 2014, an increase of 17.3 percent when compared to a year ago. Shares of Forest Laboratories have gained approximately 32.0 percent year-to-date.
Get more information on Forest Laboratories free access to the in-depth equity report at:
Illumina, Inc. (NASDAQ: ILMN) shares surged 10.14 percent to close at $90.05 a share Tuesday. The stock traded between $86.40 and $90.96 on volume of 5.13 million shares traded. The company reported revenues were $357 million for the third quarter of 2013, an increase of 25.0 percent when compared to a year ago. Shares of Illumina have gained approximately 62.0 percent year-to-date.
Get more information on Illumina and free access to the in-depth equity report at:
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) shares soared 30.0 percent to close at $1.82 a share Tuesday. The stock traded between $1.80 and $2.45 on volume of 6.18 million shares traded. The company has signed an agreement to acquire certain assets of Phyxius Pharma, including the exclusive rights to develop and commercialize levosimendan in North America. Shares of Oxygen Biotherapeutics have fallen approximately 85.0 percent year-to-date.
Get more information on Oxygen Biotherapeutics and free access to the in-depth equity report at:
PDL BioPharma Inc. (NASDAQ: PDLI) shares increased 1.62 percent to close at $8.16 a share Tuesday. The stock traded between $8.03 and $8.16 on volume of 8.16 million shares traded. The company announced that it has acquired the rights to receive royalties and milestones payable on sales of Type 2 diabetes products licensed by Depomed for $240.5 million. Shares of PDL BioPharma have gained approximately 16.0 percent year-to-date.
Get more information on PDL BioPharma and free access to the in-depth equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Five Star Equities
Leave a comment...